Following marketing authorisation of any medicinal product, the nature of the performed clinical research is mainly for review not interventional purposes. The method of administration and dosage of medicinal products are based on the Summary of Medicinal Product Characteristics (SmPC). CRO Biomapas can conduct post marketing surveillance (PMS) including tracking, collecting, and reporting of the side effects of a medicinal product and submit study report to the competent authority and sponsor. Depending on the surveillance objective, more or less complex studies are conducted with patient groups of different sizes.